Skip to main navigation Skip to search Skip to main content

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations

  • Dongho Kim
  • , Dong Wook Kim
  • , Byung Sik Cho
  • , Hyun Gyung Goh
  • , Soo Hyun Kim
  • , Wan Seok Kim
  • , Jeong Lee
  • , Il Young Kweon
  • , Sa Hee Park
  • , Jeong Hyeok Yoon
  • , Nam Doo Kim
  • , Haarin Chun
  • Catholic University of Korea
  • Catholic Univ. of Korea Coll. Med.
  • Equispharm Ltd.

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Sequential treatment with different tyrosine kinase inhibitors (TKIs) is one of the strategies for handling chronic myeloid leukemia (CML) in which dynamic change in Bcr-Abl kinase domain mutation is often an obstacle faced during TKI therapy. Here we report successful sequential therapy with different TKIs for the CML patient harboring V299L and E459K compound mutations. Molecular monitoring including quantitative analysis of BCR-ABL transcript level and mutation analysis were performed regularly for successful treatment. Additionally a drug-target complex was structurally modeled to investigate influence of amino acid substitutions on drug resistance, and to choose alternative TKI in sequential therapy, suggesting protein structural modeling can be useful approach in selecting alternative TKIs.

Original languageEnglish
Pages (from-to)1260-1265
Number of pages6
JournalLeukemia Research
Volume33
Issue number9
DOIs
StatePublished - Sep 2009

Bibliographical note

Funding Information:
This work was supported by a grant from the National Research Resource Bank Program of the Korea Science and Engineering Foundation of the Ministry of Science and Technology (No. R21-2002-000-00010-0) and by a grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (No. 01-PJ10-PG6-01GN16-0005).[J.M.B.]

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • BCR-ABL compound mutations
  • Chronic myeloid leukemia
  • Protein structural modeling
  • Sequential therapy
  • Tyrosine kinase inhibitor

Fingerprint

Dive into the research topics of 'Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations'. Together they form a unique fingerprint.

Cite this